Tenecteplase - CSPC Recomgen Pharmaceutical
Alternative Names: Mingfule; Recombinant Human TNK Tissue-type Plasminogen Activator; Recomlyse; Reflow; rhTNK-tPALatest Information Update: 13 Jun 2025
At a glance
- Originator CSPC Recomgen Pharmaceutical (Guangzhou)
- Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction
- Preregistration Ischaemic stroke
Most Recent Events
- 23 May 2025 CSPC Recomgen Pharmaceutical in collaboration with Xinqiao Hospital of Chongqing plans a phase III BRIDGE-TNK EXTEND trial for Ischaemic stroke in October 2025 (IV) (NCT06987305)
- 09 Feb 2023 Adverse events data from a phase III trial in Ischaemic stroke released by CSPC Recomgen Pharmaceutical
- 16 Nov 2022 Preregistration for Ischaemic stroke in China (IV)